Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Andreone

Showing results (141-150 of 189) with videos related to

Pageof 19
Sort By:
Cytotherapy|September 18, 2017
Molecular and functional characterization of CD133<sup>+</sup> stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cellsLucia Catani, Daria Sollazzo, Elisa Bianchi, et al.
BMC Gastroenterology|November 30, 2018
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo StudyFrancesco Giuseppe Foschi, Giorgio Bedogni, Marco Domenicali, et al.
Journal of Hepatology|March 14, 2020
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitisKris V Kowdley, Raj Vuppalanchi, Cynthia Levy, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 3, 2015
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trialPietro Andreone, Lucia Catani, Cristina Margini, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 16, 2017
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN studyXavier Forns, Marina Berenguer, Kerstin Herzer, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
World Journal of Gastroenterology|April 9, 2015
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluationStefano Gitto, Luca Saverio Belli, Ranka Vukotic, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 13, 2014
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4Gregory Everson, Curtis Cooper, Christophe Hézode, et al.
Pageof 19

Showing results (141-150 of 189) with videos related to

Sort By:
Pageof 19
Cytotherapy|September 18, 2017
Molecular and functional characterization of CD133<sup>+</sup> stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cellsLucia Catani, Daria Sollazzo, Elisa Bianchi, et al.
BMC Gastroenterology|November 30, 2018
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo StudyFrancesco Giuseppe Foschi, Giorgio Bedogni, Marco Domenicali, et al.
Journal of Hepatology|March 14, 2020
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitisKris V Kowdley, Raj Vuppalanchi, Cynthia Levy, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 3, 2015
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trialPietro Andreone, Lucia Catani, Cristina Margini, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 16, 2017
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN studyXavier Forns, Marina Berenguer, Kerstin Herzer, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
World Journal of Gastroenterology|April 9, 2015
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluationStefano Gitto, Luca Saverio Belli, Ranka Vukotic, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 13, 2014
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4Gregory Everson, Curtis Cooper, Christophe Hézode, et al.
Pageof 19